Literature DB >> 1370679

CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.

M Azuma1, M Cayabyab, D Buck, J H Phillips, L L Lanier.   

Abstract

Engagement of the CD3/T cell antigen receptor complex on small, resting T cells is insufficient to trigger cell-mediated cytotoxicity or to induce a proliferative response. In the present study, we have used genetic transfection to demonstrate that interaction of the B7-BB1 B cell activation antigen with the CD28 T cell differentiation antigen costimulates cell-mediated cytotoxicity and proliferation initiated by either anti-CD2 or anti-CD3 monoclonal antibody (mAb). Moreover, a B7-negative Burkitt's lymphoma cell line that fails to stimulate an allogeneic mixed lymphocyte response is rendered a potent stimulator after transfection with B7. The mixed leukocyte reaction proliferative response against the B7 transfectant is inhibited by either anti-CD28 or B7 mAb. We also demonstrate that freshly isolated small, resting human T cells can mediate anti-CD3 or anti-CD2 mAb-redirected cytotoxicity against a murine Fc receptor-bearing mastocytoma transfected with human B7. These preexisting cytotoxic T lymphocytes in peripheral blood are present in both the CD4 and CD8 subsets, but are preferentially within the CD45RO+ "memory" population. While small, resting T cells apparently require costimulation by CD28/B7 interactions, this requirement is lost after T cell activation. Anti-CD3 initiates a cytotoxic response mediated by in vitro cultured T cell clones in the absence of B7 ligand. The existence of functional cytolytic T cells in the small, resting T cell population may be advantageous in facilitating rapid responses to immune challenge.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370679      PMCID: PMC2119127          DOI: 10.1084/jem.175.2.353

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  38 in total

Review 1.  Is T-cell memory maintained by crossreactive stimulation?

Authors:  P C Beverley
Journal:  Immunol Today       Date:  1990-06

2.  Induction of nonspecific cytotoxicity by monoclonal anti-T3 antibodies.

Authors:  J F Leeuwenberg; H Spits; W J Tax; P J Capel
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

3.  Targeted cytotoxic cells in human peripheral blood lymphocytes.

Authors:  M A Garrido; P Perez; J A Titus; M J Valdayo; D F Winkler; S A Barbieri; J R Wunderlich; D M Segal
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

4.  Functional expression of CD28 on T cell antigen receptor gamma/delta-bearing T lymphocytes.

Authors:  R Testi; L L Lanier
Journal:  Eur J Immunol       Date:  1989-01       Impact factor: 5.532

5.  Role of T3 surface molecules in human T-cell activation: T3-dependent activation results in an increase in cytoplasmic free calcium.

Authors:  A Weiss; J Imboden; D Shoback; J Stobo
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

6.  Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens.

Authors:  L L Lanier; A M Le; J H Phillips; N L Warner; G F Babcock
Journal:  J Immunol       Date:  1983-10       Impact factor: 5.422

7.  Lysis of CD3 hybridoma targets by cloned human CD4 lymphocytes.

Authors:  A Hayward; A Boylston; P Beverley
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

8.  B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas.

Authors:  T Yokochi; R D Holly; E A Clark
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

9.  Clonal analysis of functionally distinct human CD4+ T cell subsets.

Authors:  F T Rotteveel; I Kokkelink; R A van Lier; B Kuenen; A Meager; F Miedema; C J Lucas
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

10.  The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells.

Authors:  L Koulova; E A Clark; G Shu; B Dupont
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

View more
  79 in total

1.  Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).

Authors:  R Holtappels; J Podlech; N K Grzimek; D Thomas; M F Pahl-Seibert; M J Reddehase
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype.

Authors:  Rafaela Holtappels; Doris Thomas; Jürgen Podlech; Matthias J Reddehase
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs.

Authors:  R Holtappels; M F Pahl-Seibert; D Thomas; M J Reddehase
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 4.  The role of adhesion molecules in endothelial cell accessory function.

Authors:  J R Westphal; R M de Waal
Journal:  Mol Biol Rep       Date:  1992-11       Impact factor: 2.316

5.  T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.

Authors:  L A Turka; P S Linsley; H Lin; W Brady; J M Leiden; R Q Wei; M L Gibson; X G Zheng; S Myrdal; D Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

Review 6.  Reflections on CD8 T-cell activation and memory.

Authors:  David Masopust; Rafi Ahmed
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 7.  Cancer therapy with bispecific antibodies: Clinical experience.

Authors:  Archana Thakur; Lawrence G Lum
Journal:  Curr Opin Mol Ther       Date:  2010-06

8.  CD27/CD70 interaction directly induces natural killer cell killing activity.

Authors:  F C Yang; K Agematsu; T Nakazawa; T Mori; S Ito; T Kobata; C Morimoto; A Komiyama
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

9.  T-cell receptor/CD28 engagement when combined with prostaglandin E2 treatment leads to potent activation of human T-cell leukemia virus type 1.

Authors:  Nancy Dumais; Marie-Eve Paré; Simon Mercier; Salim Bounou; Susan J Marriot; Benoit Barbeau; Michel J Tremblay
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80).

Authors:  R S McHugh; S N Ahmed; Y C Wang; K W Sell; P Selvaraj
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.